To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Marketing

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Policies/Sales

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Strategy

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).